Related Content
Publications focusing on urologic malignancies and treatments
Presented by Alicia Morgans, MD, MPH
San Francisco, California ( Dr. Alicia Morgans, Associate Professor and Medical Oncologist at Northwestern University Feinberg School of Medicine, presented some of the most influential articles from the past year in the field of prostate cancer research from a medical oncology perspective.
Presented by Henrik Gronberg, MD, PhD
Barcelona, Spain ( At the prostate cancer poster discussion at ESMO 2019, Dr. Henrik Gronberg provided a discussion of three important abstracts: the updated STAMPEDE “M1|RT Comparison”, as well as patient reported outcomes from both ENZAMET and TITAN.
Presented by Martin R. Stockler, MBBS(Hons) MSc(Clin Epi) FRACP
Barcelona, Spain (  At 2019 ASCO meeting, Davis and colleagues previously reported that treatment with enzalutamide rather than an older non-steroidal anti-androgen (bicalutamide, nilutamide, or flutamide), resulted in longer overall survival when added to standard first-line treatment,
San Francisco, CA USA ( -- Astellas Pharma Inc. and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the filing of a supplemental New Drug Application (sNDA) for XTANDI®(enzalutamide) to add an indication for the treatment of men with metastatic hormone-sensitive prostate cancer (mHSPC).
Presented by Tanya B. Dorff, MD
Chicago, IL ( The presentation of ENZAMET, overall survival (OS) results of a phase III randomized trial of standard-of-care therapy with or without enzalutamide for metastatic hormone-sensitive prostate cancer (mHSPC): ENZAMET (ANZUP 1304), an ANZUP-led international cooperative group trial, by Christopher Sweeney, MBBS, was followed by Tanya B. Dorff, MD, of City of Hope Cancer Center, who provided a discussion of this highly anticipated phase 3 trial demonstrating an OS benefit for enzalutamide vs non-steroidal anti-androgen among men with mHSPC.
Presented by Christopher Sweeney, MBBS
Chicago, IL ( Abiraterone and docetaxel are both standard of care options for available for patients with metastatic hormone-sensitive prostate cancer (mHSPC) in the United States. CHAARTED demonstrated that docetaxel improved overall survival over ADT alone and after a median of 53.7 months, the median overall survival (OS) was 57.6 months in the chemohormonal arm and 47.2 months in the ADT alone arm.
Presented by Christopher Sweeney, MBBS
Chicago, IL ( Testosterone suppression is the backbone of treatment for metastatic hormone-sensitive prostate cancer (mHSPC), however, until 2014, testosterone suppression +/- standard nonsteroidal antiandrogen was the only therapy available. Improvements in mHSPC overall survival (OS) were noted for agents that improved OS in the (castration-resistant prostate cancer) CRPC setting, notably docetaxel (CHAARTED1STAMPEDE2) and abiraterone (LATITUDE3, STAMPEDE4).